{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:14:52Z","timestamp":1790118892199,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13555-025-01596-8","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T02:51:49Z","timestamp":1763779909000},"page":"1983-1995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria"],"prefix":"10.1007","volume":"16","author":[{"given":"Gil","family":"Yosipovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Y.","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simmi","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Sugerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-Bdaoui","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-0054","authenticated-orcid":false,"given":"Sonya L.","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"3","key":"1596_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/vaccines9030303","volume":"9","author":"S Garcovich","year":"2021","unstructured":"Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines (Basel). 2021;9(3):303. https:\/\/doi.org\/10.3390\/vaccines9030303.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"1596_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/12034754211027858","volume":"26","author":"L Belmesk","year":"2022","unstructured":"Belmesk L, Muntyanu A, Cantin E, AlHalees Z, Jack CS, Le M, et\u00a0al. Prominent role of type 2 immunity in skin diseases: beyond atopic dermatitis. J Cutan Med Surg. 2022;26(1):33\u201349. https:\/\/doi.org\/10.1177\/12034754211027858.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"1596_CR3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.neuron.2018.03.023","volume":"98","author":"X Dong","year":"2018","unstructured":"Dong X, Dong X. Peripheral and central mechanisms of itch. Neuron. 2018;98(3):482\u201394. https:\/\/doi.org\/10.1016\/j.neuron.2018.03.023.","journal-title":"Neuron"},{"issue":"4","key":"1596_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jaci.2023.08.017","volume":"153","author":"B Kim","year":"2024","unstructured":"Kim B, Rothenberg ME, Sun X, Bachert C, Artis D, Zaheer R, et\u00a0al. Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms, and therapeutic targets in atopic diseases. J Allergy Clin Immunol. 2024;153(4):879\u201393. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.017.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1596_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12974-023-02882-y","volume":"20","author":"Y Ino","year":"2023","unstructured":"Ino Y, Maruyama M, Shimizu M, Morita R, Sakamoto A, Suzuki H, et\u00a0al. TSLP in DRG neurons causes the development of neuropathic pain through T cells. J Neuroinflammation. 2023;20(1):200. https:\/\/doi.org\/10.1186\/s12974-023-02882-y.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"1596_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jaci.2023.05.004","volume":"152","author":"L Misery","year":"2023","unstructured":"Misery L, Pierre O, Le Gall-Ianotto C, Lebonvallet N, Chernyshov PV, Le Garrec R, et\u00a0al. Basic mechanisms of itch. J Allergy Clin Immunol. 2023;152(1):11\u201323. https:\/\/doi.org\/10.1016\/j.jaci.2023.05.004.","journal-title":"J Allergy Clin Immunol"},{"key":"1596_CR7","doi-asserted-by":"publisher","first-page":"1272230","DOI":"10.3389\/fnmol.2023.1272230","volume":"16","author":"O Mahmoud","year":"2023","unstructured":"Mahmoud O, Oladipo O, Mahmoud RH, Yosipovitch G. Itch: from the skin to the brain\u2013peripheral and central neural sensitization in chronic itch. Front Mol Neurosci. 2023;16:1272230. https:\/\/doi.org\/10.3389\/fnmol.2023.1272230.","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"1596_CR8","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","volume":"142","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142(5):1375\u201390. https:\/\/doi.org\/10.1016\/j.jaci.2018.09.005.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1596_CR9","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/1744666X.2021.2000390","volume":"17","author":"G Ingrasci","year":"2021","unstructured":"Ingrasci G, Lipman ZM, Yosipovitch G. When topical therapy of atopic dermatitis fails: a guide for the clinician. Expert Rev Clin Immunol. 2021;17(12):1245\u201356. https:\/\/doi.org\/10.1080\/1744666X.2021.2000390.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"1596_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","volume":"10","author":"BE Kim","year":"2018","unstructured":"Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10(3):207\u201315. https:\/\/doi.org\/10.4168\/aair.2018.10.3.207.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1596_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.644760","volume":"8","author":"FJ Legat","year":"2021","unstructured":"Legat FJ. Itch in atopic dermatitis\u2014what is new? Front Med (Lausanne). 2021;8:644760. https:\/\/doi.org\/10.3389\/fmed.2021.644760.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"1596_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2340\/00015555-2263","volume":"96","author":"SE Marron","year":"2016","unstructured":"Marron SE, Tomas-Aragonas L, Boira S, Campos-Rodenas R. Quality of life, emotional wellbeing and family repercussions in dermatological patients experiencing chronic itch: a pilot study. Acta Derm Venerol. 2016;96(3):331\u20135. https:\/\/doi.org\/10.2340\/00015555-2263.","journal-title":"Acta Derm Venerol"},{"issue":"3","key":"1596_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jaad.2020.08.035","volume":"84","author":"T Hawro","year":"2021","unstructured":"Hawro T, Przyby\u0142owicz K, Spindler M, Hawro M, Ste\u0107 M, Altrichter S, et\u00a0al. The characteristics and impact of pruritus in adult dermatology patients: a prospective, cross-sectional study. J Am Acad Dermatol. 2021;84(3):691\u2013700. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.035.","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"1596_CR14","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et\u00a0al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. New Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"New Engl J Med"},{"issue":"10086","key":"1596_CR15","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et\u00a0al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"5","key":"1596_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, Kwatra SG, Kim BS, Laws E, et\u00a0al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180\u201390. https:\/\/doi.org\/10.1038\/s41591-023-02320-9.","journal-title":"Nat Med"},{"key":"1596_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jdin.2024.03.025","volume":"16","author":"G Yosipovitch","year":"2024","unstructured":"Yosipovitch G, Kim BS, Kwatra SG, Mollanazar NK, St\u00e4nder S, Satoh T, et\u00a0al. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2). JAAD Int. 2024;16:163\u201374. https:\/\/doi.org\/10.1016\/j.jdin.2024.03.025.","journal-title":"JAAD Int"},{"issue":"1","key":"1596_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Gim\u00e9nez-Arnau AM, Bernstein JA, et\u00a0al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184\u201394. https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1596_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, Eckert L, Abb\u00e9 A, Nelson L, et\u00a0al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139. https:\/\/doi.org\/10.1111\/bjd.17744.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1596_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jamadermatol.2024.1634","volume":"160","author":"SG Kwatra","year":"2024","unstructured":"Kwatra SG, Yosipovitch G, Kim B, Stander S, Rhoten S, Ivanescu C, et\u00a0al. Worst Itch Numeric Rating Scale for prurigo nodularis: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol. 2024;160(8):813\u201321. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1634.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1596_CR21","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s13555-023-00955-7","volume":"13","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Soong W, Bernstein JA. Chronic spontaneous urticaria: how to measure it and the need to define treatment success. Dermatol Ther (Heidelb). 2023;13(8):1629\u201346. https:\/\/doi.org\/10.1007\/s13555-023-00955-7.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"1596_CR22","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s13555-023-00999-9","volume":"13","author":"SG Kwatra","year":"2023","unstructured":"Kwatra SG, Rodriguez D, Dias-Barbosa C, Budhiarso I, Fofana F, Vernon M, et\u00a0al. Validation of the Peak Pruritus Numerical Rating Scale as a patient-reported outcome measure in prurigo nodularis. Dermatol Ther (Heidelb). 2023;13(10):2403\u201316. https:\/\/doi.org\/10.1007\/s13555-023-00999-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1596_CR23","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.anai.2022.08.538","volume":"129","author":"M Maurer","year":"2022","unstructured":"Maurer M, Casale T, Saini S, Ben-Shoshan M, Radin A, Akinlade B, et\u00a0al. Dupilumab efficacy in patients with chronic spontaneous urticaria by IgE level: LIBERTY-CSU CUPID Study A. Ann Allergy Asthma Immunol. 2022;129(5):S11. https:\/\/doi.org\/10.1016\/j.anai.2022.08.538.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"1596_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et\u00a0al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459\u201373. https:\/\/doi.org\/10.1111\/bjd.17869.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1596_CR25","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.anai.2024.10.005","volume":"133","author":"T Casale","year":"2024","unstructured":"Casale T, Saini S, Bernstein J, Gim\u00e9nez-Arnau A, Bauer D, Amin N, et\u00a0al. Dupilumab significantly improves itch and hives in patients with chronic spontaneous urticaria (CUPID study C). Ann Allergy Asthma Immunol. 2024;133(6):S2. https:\/\/doi.org\/10.1016\/j.anai.2024.10.005.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"1596_CR26","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s13555-022-00737-7","volume":"12","author":"EB Haddad","year":"2022","unstructured":"Haddad EB, Cyr SL, Arima K, McDonald RK, Levit NA, Nestle FO. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther (Heidelb). 2022;12(7):1501\u201333. https:\/\/doi.org\/10.1007\/s13555-022-00737-7.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1596_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350. https:\/\/doi.org\/10.1038\/nrd4624.","journal-title":"Nat Rev Drug Discov"},{"key":"1596_CR28","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","volume":"9","author":"IS Juntilla","year":"2018","unstructured":"Juntilla IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888. https:\/\/doi.org\/10.3389\/fimmu.2018.00888.","journal-title":"Front Immunol"},{"issue":"1","key":"1596_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et\u00a0al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-28.e13. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell"},{"issue":"2","key":"1596_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jaci.2013.03.050","volume":"132","author":"B Stott","year":"2013","unstructured":"Stott B, Lavender P, Lehmann S, Pennino D, Durham S, Schmidt-Weber CB. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J Allergy Clin Immunol. 2013;132(2):446-54.e5. https:\/\/doi.org\/10.1016\/j.jaci.2013.03.050.","journal-title":"J Allergy Clin Immunol"},{"key":"1596_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbi.2021.08.211","volume":"98","author":"S Xiao","year":"2021","unstructured":"Xiao S, Lu Z, Steinhoff M, Li Y, Buhl T, Fischer M, et\u00a0al. Innate immune regulates cutaneous sensory IL-13 receptor alpha 2 to promote atopic dermatitis. Brain Behav Immun. 2021;98:28\u201339. https:\/\/doi.org\/10.1016\/j.bbi.2021.08.211.","journal-title":"Brain Behav Immun"},{"issue":"1","key":"1596_CR32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54\u201362. https:\/\/doi.org\/10.1111\/all.13954.","journal-title":"Allergy"},{"issue":"3","key":"1596_CR33","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaci.2022.01.028","volume":"150","author":"Y Miron","year":"2022","unstructured":"Miron Y, Miller PE, Hughes C, Indersmitten T, Lerner EA, Cevikbas F. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti\u2013IL-13 mAb. J Allergy Clin Immunol. 2022;150(3):690\u2013700. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.028.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1596_CR34","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.jaip.2021.03.033","volume":"9","author":"AM Gim\u00e9nez-Arnau","year":"2021","unstructured":"Gim\u00e9nez-Arnau AM, de Montjoye L, Asero R, Cugno M, Kulthanan K, Yanase Y, et\u00a0al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells. J Allergy Clin Immunol Pract. 2021;9(6):2195\u2013208. https:\/\/doi.org\/10.1016\/j.jaip.2021.03.033.","journal-title":"J Allergy Clin Immunol Pract"}],"updated-by":[{"DOI":"10.1007\/s13555-026-01671-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01596-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:38:05Z","timestamp":1775101085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01596-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01596-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-026-01671-8","URL":"https:\/\/doi.org\/10.1007\/s13555-026-01671-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gil Yosipovitch is an advisory board member for AbbVie, Amgen, Arcutis Biotherapeutics, Attovia, Eli Lilly, Escient Pharmaceuticals, Galderma, GSK, Incyte, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., Sanofi, and Vifor; has received grants\/research funding from Amgen, Celldex, Eli Lilly, Escient Pharmaceuticals, Galderma, Kiniksa, LEO Pharma, Novartis, Pfizer, Sanofi-Regeneron Pharmaceuticals Inc.; is an investigator for Regeneron Pharmaceuticals Inc. and Sanofi; and provides research support and is a consultant for Regeneron Pharmaceuticals Inc. Brian S. Kim is a consultant for AbbVie, Abrax Japan, Almirall, Alys Pharmaceuticals, Cara Therapeutics, Clexio Biosciences, Eli Lilly, Escient Pharmaceuticals, Evommune, Galderma, Neurommune Therapeutics, Novartis, Pfizer, RecensMedical, Regeneron Pharmaceuticals Inc., Sanofi, and Septerna; and he is also co-founder of Alys Pharmaceuticals and Neurommune Therapeutics. John Y. Koo has been a speaker and\/or consultant for AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Castle, Dermavant, Eli Lilly, EPI, Incyte, Janssen, LEO\u00a0Pharma, Novartis, Ortho Dermatologics\/Valeant, Pfizer, Regeneron Pharmaceuticals Inc.\/Sanofi, Sun, and UCB. Zhen Chen, Joseph Zahn, and Sonya L. Cyr are employees and shareholders of Regeneron Pharmaceuticals Inc. Simmi Wiggins, Philip Sugerman, and El-Bdaoui Haddad are Sanofi employees and may hold stock and\/or stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The studies included in this analysis were conducted in accordance with the protocol and consensus ethical principles derived from international guidelines, including the Declaration of Helsinki (1964) and other applicable laws and regulations. Authors received participants\u2019 consent to participate. Each participant provided written informed consent to participate and publish prior to their participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}